Acquiring Company
Natera
Acquired Company
Invitae
AustinSan FranciscoBiotechnologyHealth CareGeneticsHealth DiagnosticsBiotechnologyDescription
Natera, Inc. has acquired certain assets related to non-invasive prenatal screening and carrier screening business from Invitae, a leading medical genetics company. This strategic acquisition is aligned with Natera’s commitment to providing excellent service and aims to support additional patients and providers.
Other recent acquisitions in Genetics and Health Diagnostics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (January 18, 2024)
- Branded Legacy, Inc. signs letter of intent to purchase Sycamore BioPharma, LLC, to strengthen its position in the BioTech industry (March 1, 2024)
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (February 16, 2024)
- Novo Holdings to Acquire Catalent (February 5, 2024)
- Medline Industries, LP completes acquisition of AG Cuffill® from Hospitech Respiration Ltd. (March 7, 2024)
- Haemonetics to acquire Attune Medical to enhance patient care solutions (March 5, 2024)
Who to call at Natera, and when
When Natera changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Natera raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Natera, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Natera. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Natera makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Invitae?
Invitae was acquired by Natera, based in Austin. The deal was reported on January 22, 2024. Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Natera is publicly traded (NTRA) and operates in Biotechnology.
When did Natera acquire Invitae?
Natera's acquisition of Invitae was reported on January 22, 2024. Natera, Inc. has acquired certain assets related to non-invasive prenatal screening and carrier screening business from Invitae, a leading medical genetics company. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Invitae do?
Invitae is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. It is privately held, operating in Biotechnology, and is based in San Francisco.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.